MAP2K1 and cystic fibrosis: Future preclinical studies to provide additional rigorous assessment of the impact on inflammation, host defense, and the antimicrobial potential of MEK1/2 inhibitor compounds should be performed with the goal of developing a path to human CF translational studies.